Deutsche Bank set a €96.00 ($111.63) price target on Merck KGaA (FRA:MRK) in a research note published on Friday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
A number of other research firms have also recently commented on MRK. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the company a neutral rating in a research note on Friday. Barclays set a €82.00 ($95.35) target price on Merck KGaA and gave the company a sell rating in a research note on Monday, May 27th. Kepler Capital Markets set a €108.00 ($125.58) target price on Merck KGaA and gave the company a buy rating in a research note on Monday, June 17th. UBS Group set a €99.00 ($115.12) target price on Merck KGaA and gave the company a neutral rating in a research note on Thursday. Finally, Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the company a neutral rating in a research note on Friday. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of €100.05 ($116.34).
Shares of MRK stock traded up €0.30 ($0.35) on Friday, reaching €94.86 ($110.30). The company’s stock had a trading volume of 484,060 shares. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72). The company has a 50 day simple moving average of €93.46.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: Return On Assets
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.